We are proud to announce that PhenoPath is now a Quest Diagnostics Company.
This real time quantitative (RQ) PCR assay is performed on RNA extracted from fresh bone marrow or peripheral blood specimens. Results are reported as a ratio of p190 transcript to ABL1 transcript. This test is indicated in the following settings: • To confirm the diagnosis of CML and ALL in new patients whose blood count suggests the diagnosis of a chronic myeloproliferative disorder or ALL. • To monitor response to therapy in ALL. • To monitor response to therapy in CML: In Chronic myelogenous leukemia (CML), RQ-BCR-ABL mbcr PCR is recommended to be performed on a peripheral blood specimen in every new patient prior to therapy and then afterwards at 3 month intervals to monitor patient responsiveness to anti-tyrosine kinase therapy. Once complete cytogenetic remission is achieved BCR-ABL mbcr transcript monitoring can be reduced to every 12 months. Type: Reverse Transcription PCR, Quantitative
Disease State: Precursor B-Lymphoblastic Lymphoma/Leukemia (B-ALL)
CPT Code(s): 81207 (reference only; CPTs may vary)
Turnaround Time: Within 4-8 business days of receipt
• Specimen MUST be received within 48 hrs of collection • Peripheral blood, Preferred: 5 ml in EDTA (purple top) / Acceptable: 5 ml in sodium heparin (green top) - OR - • Bone marrow aspirate, Preferred: 1-2 ml in EDTA (purple top) / Acceptable: 1-2 ml in sodium heparin (green top)